Home > Boards > US Listed > Medical - Drugs > Abbvie Inc (ABBV)

https://www.fiercebiotech.com/biotech/abbvie-posts-pivotal-data-age-related-long-sightedness-drug

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
lilLu Member Profile
Member Level 
Followed By 4
Posts 991
Boards Moderated 5
Alias Born 04/13/21
160x600 placeholder
ANI Pharmaceuticals launches generic version of AbbVie's Bystolic Seeking Alpha - 9/17/2021 7:56:31 AM
AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis Dow Jones News - 9/16/2021 8:43:00 AM
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire (US) - 9/16/2021 8:00:00 AM
This Warren Buffet Stock Could Rise, Following Setback TipRanks - 9/13/2021 3:24:40 PM
Regenxbio Shares Jump After Collaborating With AbbVie on Eye Therapy Dow Jones News - 9/13/2021 11:25:00 AM
AbbVie, Regenxbio to Partner on Eye Therapy Dow Jones News - 9/13/2021 7:11:00 AM
AbbVie and REGENXBIO Announce Eye Care Collaboration PR Newswire (US) - 9/13/2021 6:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2021 5:02:17 PM
AbbVie Declares Quarterly Dividend PR Newswire (US) - 9/10/2021 10:27:00 AM
AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021 PR Newswire (US) - 9/10/2021 9:00:00 AM
AbbVie to Present at the Morgan Stanley Healthcare Conference PR Newswire (US) - 9/9/2021 8:00:00 AM
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet PR Newswire (US) - 9/9/2021 7:00:00 AM
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet Business Wire - 9/9/2021 7:00:00 AM
AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress PR Newswire (US) - 9/8/2021 9:10:00 AM
Alector slides as two top executives plan to leave Seeking Alpha - 9/8/2021 8:04:15 AM
Vertex slides as Morgan Stanley cuts rating on competitive threat from AbbVie Seeking Alpha - 9/7/2021 10:24:49 AM
Is AbbVie’s Arthritis “Heartache” Curable? TipRanks - 9/2/2021 6:05:44 AM
AbbVie Down Over 8%, on Pace for Largest Percent Decrease Since March 2020 -- Data Talk Dow Jones News - 9/1/2021 12:15:00 PM
5 Top Dividend Stocks for September 2021 TipRanks - 8/30/2021 5:30:00 AM
AbbVie reçoit une recommandation favorable de la part du Comité d'experts en examen du Programme pancanadien d'évaluation des anticancéreux (PPEA) de l'Agence canadienne des médicaments et des technologies de la santé (ACMTS) pour le remboursement... PR Newswire (Canada) - 8/26/2021 10:01:00 AM
AbbVie Receives a Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for VENCLEXTA® (venetoclax) in Combination with azacitidine f... PR Newswire (Canada) - 8/26/2021 10:01:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/25/2021 6:09:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/25/2021 6:09:36 PM
AbbVie Gets European OK of Rinvoq in Atopic Dermatitis Dow Jones News - 8/24/2021 8:41:00 AM
European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis PR Newswire (US) - 8/24/2021 8:00:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences